Liraglutide for the Treatment of Antipsychotic Drug-Induced Weight Gain-Reply
JAMA Psychiatry
.
2017 Nov 1;74(11):1173-1174.
doi: 10.1001/jamapsychiatry.2017.2702.
Authors
Anders Fink-Jensen
1
2
,
Christoph U Correll
3
4
5
6
,
Tina Vilsbøll
2
7
8
Affiliations
1
Psychiatric Centre Copenhagen, University Hospital Copenhagen and Laboratory of Neuropsychiatry, University of Copenhagen, Copenhagen, Denmark.
2
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
3
Psychiatry Research, Zucker Hillside Hospital, Northwell Health, Glen Oaks, New York.
4
Department of Psychiatry and Molecular Medicine, Hofstra Northwell School of Medicine, Hempstead, New York.
5
Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, New York.
6
Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine, Bronx, New York.
7
Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.
8
Steno Diabetes Center Copenhagen, University of Copenhagen, Copenhagen, Denmark.
PMID:
28973062
DOI:
10.1001/jamapsychiatry.2017.2702
No abstract available
Publication types
Comment
MeSH terms
Antipsychotic Agents*
Humans
Hypoglycemic Agents
Liraglutide*
Weight Gain / drug effects
Substances
Antipsychotic Agents
Hypoglycemic Agents
Liraglutide